Based on the database of drug targets in 324 human cancer cell lines from 30 cancer types (51), we found that EGFR is an anti-cancer target in Squamous Cell Lung Carcinoma, Lung Adenocarcinoma, Oral Cavity Carcinoma, Ovarian Carcinoma, Head and Neck Carcinoma and Esophagus. This evidence concerns the gene EGFR and oral cavity carcinoma.